MEI Pharma and Kyowa Kirin Announces ME-401 Phase 1b Study to be Highlighted in a Presentation at the Virtual Edition of the 25th European Hematology Association Annual Congress
SAN DIEGO and TOKYO, May 14, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that updated Phase 1b data on ME-401, its investigational oral phosphatidylinositol 3-kinase delta (PI3K ) inhibitor drug-candidate in clinical development for the treatment of follicular lymphoma and other B-cell malignancies, will be presented in a poster session at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress to be held June 11 to June 14, 2020.
Presentation at EHA25 Virtual Congress
Title: The PI3k Inhibitor ME-401 is Well-Tolerated on Intermittent Schedule and Produces a High-Rate of Durable Responses in Relapsed/Refractory (R/R) Indolent B-Cell Malignancies
Session Title: Indolent and mantle-cell non-Hodgkin lymphoma - Clinical
Authors: John Pagel, et. al.
Abstract ID: EP1174
Session Type: Poster
The abstract is available on the EHA Annual Congress website. Presentations and posters will be available on the EHA website for on-demand viewing beginning on June 12, 2020 at 8:30 a.m. ET.
About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. Our portfolio of drug candidates contains four clinical-stage assets, including one candidate in an ongoing global registration trial and another candidate in a Phase 2 clinical trial which may support an accelerated approval marketing application with the U.S. Food and Drug Administration. Each of our pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic options. For more information, please visit www.meipharma.com.
About Kyowa Kirin
Kyowa Kirin commits to innovative drug discovery driven by state-of-the-art technologies. The company focuses on creating new value in four therapeutic areas: nephrology, oncology, immunology/allergy and neurology. Under the Kyowa Kirin brand, employees from 40 group companies across North America, EMEA and Asia/Oceania unite to champion the interests of patients and their caregivers by discovering solutions to address unmet medical needs. You can learn more about the business of Kyowa Kirin at www.kyowakirin.com.
Forward-Looking Statements
Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; the impact of the COVID-19 pandemic on our industry and individual companies, including on our counterparties, the supply chain, the execution of our clinical development programs, our access to financing and the allocation of government resources; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
View original content to download multimedia:http://www.prnewswire.com/news-releases/mei-pharma-and-kyowa-kirin-announces-me-401-phase-1b-study-to-be-highlighted-in-a-presentation-at-the-virtual-edition-of-the-25th-european-hematology-association-annual-congress-301059489.html
SOURCE MEI Pharma, Inc.
